Skip to main content
Canna~Fangled Abstracts

Experience With Medical Marijuana for Cancer Patients in the Palliative Setting

By June 28, 2022August 2nd, 2022No Comments

. 2022 Jun 28;14(6):e26406.

doi: 10.7759/cureus.26406. eCollection 2022 Jun.

Karna T Sura 1, Leslie Kohman 2, Danning Huang 3, Silviu V Pasniciuc 4
Affiliations 

Abstract

Objectives: Medical marijuana is a symptom treatment option for palliative cancer patients; however, its useful applications remain limited. The goals of this study were to review the characteristics of patients who received medical marijuana under our ambulatory palliative care program and to determine barriers to access and use of medical marijuana in this population.

Methods: This study was a retrospective analysis of patients who were enrolled in the medical marijuana registry through the ambulatory palliative care department at Upstate Cancer Center. Data from June 2017 to June 2020 were analyzed. Patients were included if they had a diagnosis of cancer, were certified by a qualified practitioner in the New York Medical Marijuana Program, and received care at Upstate Medical University. Patients were excluded if no marijuana certificate was found or if they transferred care.

Results: The study population was 184 patients. Ninety-three patients (51.5%) received at least one prescription from a New York licensed marijuana dispensary while 72 (39.13%) were certified but never obtained any medical marijuana. For patients who took at least one dose of medical marijuana, 48.14% experienced an improvement in pain, 44.95% used fewer opioids, and 85.11% had an improvement in at least one symptom. Adverse effects were low at 3.72%.

Conclusion: Medical marijuana has an important role in the palliation of symptoms in advanced cancers with few adverse effects. There are still many barriers to effective use. More prospective research is needed to optimize delivery and dosing.

Keywords: cancer, medical marijuana, palliative care, quality of life, terminal care

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1

References

    1. Systematic review and meta-analysis of cannabinoids in palliative medicine. Mücke M, Weier M, Carter C, et al. J Cachexia Sarcopenia Muscle. 2018;9:220–234. – PMC – PubMed
    1. Medical marijuana use in oncology: a review. Wilkie G, Sakr B, Rizack T. JAMA Oncol. 2016;2:670–675. – PubMed
    1. Bodine M, Kemp AK. StatPearls [Internet] Treasure Island, FL: StatPearls Publishing; 2022. Medical cannabis use in oncology. – PubMed
    1. The management of cancer symptoms and treatment-induced side effects with cannabis or cannabinoids. Sexton M, Garcia JM, Jatoi A, Clark CS, Wallace MS. J Natl Cancer Inst Monogr. 2021;2021:86–98. – PMC – PubMed
    1. Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. Carter GT, Flanagan AM, Earleywine M, Abrams DI, Aggarwal SK, Grinspoon L. Am J Hosp Palliat Care. 2011;28:297–303. – PubMed

Leave a Reply